Literature DB >> 15312979

Specific localized expression of cGMP PDEs in Purkinje neurons and macrophages.

Andrew T Bender1, Joseph A Beavo.   

Abstract

As cGMP hydrolyzing cyclic nucleotide phosphodiesterases (PDEs) have diverse regulatory and catalytic properties, the specific cGMP PDEs a cell expresses will determine the duration and intensity of a cGMP signal. This, in turn, results in different cellular responses between cell types and tissues. Therefore, identifying which cGMP PDEs are expressed in different tissues and cell types could increase our understanding of physiological and pathological processes. The brain is one area where large numbers of diverse cGMP PDEs are expressed in specific regions and cell types. A case in point is differential expression of cGMP PDEs in neuronal cells. For example, we have recently found that PDE5 is expressed in all Purkinje neurons while PDE1B is expressed in only a subset of these neurons. The expression of PDE2 has also been found to be selective for discrete populations of neurons. Another example of selective cGMP PDE expression is seen with cytokine-induced differentiation of monocytes to macrophages. We have recently discovered that monocyte differentiation with the cytokine macrophage colony-stimulating factor (M-CSF) causes an upregulation of PDE2 and a small increase in PDE1B while granulocyte-macrophage colony-stimulating factor (GM-CSF) causes a large increase in PDE1B but a decrease in PDE2. These same cytokines can influence the phenotype of microglial cells and are likely to affect their expression of cGMP PDEs. In this report, we present recent results from our laboratory and review earlier findings illustrating the concept of highly specific expression of cGMP PDEs and discuss how this may be important for understanding brain function and dysfunction.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15312979     DOI: 10.1016/j.neuint.2004.03.015

Source DB:  PubMed          Journal:  Neurochem Int        ISSN: 0197-0186            Impact factor:   3.921


  23 in total

1.  Mechanisms Involved in the Remyelinating Effect of Sildenafil.

Authors:  Daniela Díaz-Lucena; María Gutierrez-Mecinas; Beatriz Moreno; José Lupicinio Martínez-Sánchez; Paula Pifarré; Agustina García
Journal:  J Neuroimmune Pharmacol       Date:  2017-08-03       Impact factor: 4.147

Review 2.  Regulation and function of cyclic GMP-mediated pathways in glial cells.

Authors:  María Antonia Baltrons; Mariela Susana Borán; Paula Pifarré; Agustina García
Journal:  Neurochem Res       Date:  2008-04-01       Impact factor: 3.996

3.  Phosphodiesterase 2A is a major negative regulator of iNOS expression in lipopolysaccharide-treated mouse alveolar macrophages.

Authors:  Otgonchimeg Rentsendorj; Franco R D'Alessio; David B Pearse
Journal:  J Leukoc Biol       Date:  2014-07-25       Impact factor: 4.962

4.  A phosphodiesterase 2A isoform localized to mitochondria regulates respiration.

Authors:  Rebeca Acin-Perez; Michael Russwurm; Kathrin Günnewig; Melanie Gertz; Georg Zoidl; Lavoisier Ramos; Jochen Buck; Lonny R Levin; Joachim Rassow; Giovanni Manfredi; Clemens Steegborn
Journal:  J Biol Chem       Date:  2011-07-01       Impact factor: 5.157

5.  Knockdown of lung phosphodiesterase 2A attenuates alveolar inflammation and protein leak in a two-hit mouse model of acute lung injury.

Authors:  Otgonchimeg Rentsendorj; Mahendra Damarla; Neil R Aggarwal; Ji-Young Choi; Laura Johnston; Franco R D'Alessio; Michael T Crow; David B Pearse
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2011-05-13       Impact factor: 5.464

Review 6.  Cyclic nucleotides and phosphodiesterases in monocytic differentiation.

Authors:  Angie L Hertz; Joseph A Beavo
Journal:  Handb Exp Pharmacol       Date:  2011

7.  NMDA receptors and the L-arginine-nitric oxide-cyclic guanosine monophosphate pathway are implicated in the antidepressant-like action of the ethanolic extract from Tabebuia avellanedae in mice.

Authors:  Andiara E Freitas; Morgana Moretti; Josiane Budni; Grasiela O Balen; Sinara C Fernandes; Patricia O Veronezi; Melina Heller; Gustavo A Micke; Moacir G Pizzolatti; Ana Lúcia S Rodrigues
Journal:  J Med Food       Date:  2013-11       Impact factor: 2.786

8.  Repurposing erectile dysfunction drugs tadalafil and vardenafil to increase bone mass.

Authors:  Se-Min Kim; Charit Taneja; Helena Perez-Pena; Vitaly Ryu; Anisa Gumerova; Wenliang Li; Naseer Ahmad; Ling-Ling Zhu; Peng Liu; Mehr Mathew; Funda Korkmaz; Sakshi Gera; Damini Sant; Elina Hadelia; Kseniia Ievleva; Tan-Chun Kuo; Hirotaka Miyashita; Li Liu; Irina Tourkova; Sarah Stanley; Daria Lizneva; Jameel Iqbal; Li Sun; Ronald Tamler; Harry C Blair; Maria I New; Shozeb Haider; Tony Yuen; Mone Zaidi
Journal:  Proc Natl Acad Sci U S A       Date:  2020-06-08       Impact factor: 11.205

9.  Design of novel β-carboline derivatives with pendant 5-bromothienyl and their evaluation as phosphodiesterase-5 inhibitors.

Authors:  Dalia S El-Gamil; Nermin S Ahmed; Bernard D Gary; Gary A Piazza; Matthias Engel; Rolf W Hartmann; Ashraf H Abadi
Journal:  Arch Pharm (Weinheim)       Date:  2013-01       Impact factor: 3.751

10.  L-arginine supplementation reduces cardiac noradrenergic neurotransmission in spontaneously hypertensive rats.

Authors:  Chee-Wan Lee; Dan Li; Keith M Channon; David J Paterson
Journal:  J Mol Cell Cardiol       Date:  2009-04-09       Impact factor: 5.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.